A5033066280- Viral-associated cancers and disorders
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Cytomegalovirus and herpesvirus research
- Parvovirus B19 Infection Studies
- Eosinophilic Disorders and Syndromes
- Histiocytic Disorders and Treatments
- Polyomavirus and related diseases
- T-cell and Retrovirus Studies
- T-cell and B-cell Immunology
- Herpesvirus Infections and Treatments
- NF-κB Signaling Pathways
- Immunotherapy and Immune Responses
- Chronic Lymphocytic Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Autoimmune and Inflammatory Disorders Research
- Virus-based gene therapy research
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Biochemical and Molecular Research
- Adenosine and Purinergic Signaling
- Animal Virus Infections Studies
- Epigenetics and DNA Methylation
- Acute Lymphoblastic Leukemia research
- Respiratory viral infections research
University of Birmingham
2009-2019
Boston University
2015
Cancer Research UK
1993-2013
Cancer Research UK Clinical Trials Unit
1985-2012
Worcestershire County Council
2010
Cardiff University
2005-2006
University of Wales
1997-2006
Leiden University Medical Center
2005
Tenovus Cancer Care
1995-2003
Hallym University
2001
Epstein-Barr virus, a human herpesvirus that persists within the B-lymphoid system, can enhance survival potential of latently infected B cells in vitro through up-regulation cellular protein Bcl-2. The possibility an analogous effect is operative lytically was suggested by observation distant sequence homology between virus-coded early lytic cycle protein, BHRF1, and Here we show gene transfer BHRF1 resembles Bcl-2 both its subcellular localization capacity to B-cell survival. Thus confocal...
Latent Epstein-Barr virus (EBV) infection and growth transformation of B lymphocytes is characterized by EBV nuclear membrane protein expression (EBV antigen [EBNA] latent [LMP], respectively). LMP1 known to be an oncogene in rodent fibroblasts induce B-lymphocyte activation cellular adhesion molecules the EBV-negative Burkitt's lymphoma cell line Louckes. EBNA-2 required for EBV-induced transformation; it lowers fibroblast serum dependence specifically induces CD23 Louckes cells. These...
Epstein-Barr virus (EBV), a human herpes with oncogenic potential, persists in B lymphoid tissues and is controlled by virus-specific cytotoxic T lymphocyte (CTL) surveillance. On reactivation vitro, these CTLs recognize EBV-transformed lymphoblastoid cell lines (LCLs) an HLA class I antigen-restricted fashion, but the viral antigens providing target epitopes for such recognition remain largely undefined. Here we have tested EBV-induced polyclonal CTL preparations from 16 virus-immune donors...
Expression of the Epstein-Barr virus (EBV) encoded nuclear antigens (EBNA 1 to 6) and membrane-associated protein (LMP) was investigated by immunoblotting in 83 nasopharyngeal carcinoma (NPC) biopsies 25 other tumor normal tissue specimens from head neck region. Fifty-eight NPC were large enough yield parallel data on DNA viral expression. All 16 cases clinically diagnosed histologically confirmed NPCs North Africa contained EBV expressed EBNA-1. Of 31 China, 29 these One control biopsy...
Epstein-Barr virus (EBV) infection of EBV-negative Burkitt lymphoma (BL) cells induces some changes similar to those seen in normal B lymphocytes that have been growth transformed by EBV. The role individual EBV genes this process was evaluated introducing each the viral are normally expressed growth-transformed and latently infected lymphoblasts into an BL cell line, using recombinant retrovirus-mediated transfer. Clones were derived stably express nuclear antigen 1 (EBNA-1), EBNA-2,...
Epstein-Barr virus (EBV) isolates show sequence divergence in the BamHI YH region of genome which encodes nuclear antigen EBNA 2, a protein thought to be involved initiation virus-induced B-cell transformation; type A (such as B95-8 EBV) encode 82- 87-kilodalton 2A protein, whereas B AG876 an antigenically distinct 75-kilodalton 2B protein. In present work 12 and 8 have been compared for their ability transform resting human cells vitro into permanent lymphoblastoid cell lines. Although...
Previous studies on Epstein-Barr virus (EBV)-positive B-cell lines have identified two distinct forms of latency. Lymphoblastoid cell generated by virus-induced transformation normal B cells in vitro, express the full spectrum six EBNAs and three latent membrane proteins (LMP1, LMP2A, LMP2B); furthermore, these often contain a small fraction spontaneously entering lytic cycle. In contrast, Burkitt's lymphoma-derived retaining tumor biopsy phenotype only one proteins, nuclear antigen EBNA1;...
Epstein-Barr virus (EBV)-positive Burkitt's lymphoma (BL) biopsy cells and early passage BL cell lines have been reported as showing an unusual type of virus-cell interaction; at least two EBV latent proteins appear not to be expressed. Serial such is often accompanied by a broadening gene expression corresponding change in the surface/growth phenotype towards that shown vitro transformed lymphoblastoid (LCLs). The sequence events, both viral cellular, involved this transition needs defined...
When human peripheral blood lymphocytes (PBLs) from Epstein-Barr virus (EBV)-seropositive donors are injected intraperitoneally into SCID mice, EBV+ B cell tumors develop within weeks. A preliminary report (Mosier, D. E., R. J. Gulizia, S. M. Baird, Richman, B. Wilson, I. Fox, and T. Kipps, 1989. Blood. 74(Suppl. 1):52a) has suggested that such resemble the EBV-positive malignancy, Burkitt's lymphoma. The present work shows generally (hu) PBL-SCID distinct lymphoma instead lymphoblastoid...
Monoclonal antibodies specific for the 'latent membrane protein' (LMP) of Epstein-Barr virus (EBV), one effector proteins EBV-induced B cell transformation, have been generated from mice immunized with a beta-galactosidase fusion protein containing carboxyl half B95.8 strain LMP sequence. Four monoclonal IgG1 antibodies, designated CS.1, CS.2, CS.3 and CS.4, which together recognized at least three different epitopes on molecule, were used to examine various aspects expression in lines...
Cytotoxic T lymphocytes (CTLs) control viral infections by recognizing peptides presented major histocompatibility complex (MHC) class I molecules. Human leukocyte antigen (HLA)-A11-restricted CTLs that recognize peptide residues 416 to 424 of the Epstein-Barr virus (EBV) nuclear antigen-4 frequently dominate EBV-induced responses in A11 + Caucasian donors. This epitope is conserved type A EBV strains from Caucasians and central African populations, where relatively infrequent. However,...
The BZLF1 protein of Epstein-Barr virus (EBV) is a key immediate-early which has been shown to disrupt latency in EBV-infected B cells. We have generated monoclonal antibody, BZ1, reacts immunohistology, immunoblotting, and immunoprecipitation recognizes both the active, dimeric form inactive, monomeric protein. Biopsies oral hairy leukoplakia, an AIDS-associated lesion characterized by high-level EBV replication, were examined immunohistochemistry using BZ1 antibody. A...
Relatively little is known about immune evasion during the productive phase of infection by γ 1 -herpesvirus Epstein–Barr virus (EBV). The use a unique system to isolate cells in lytic cycle allowed us identify host shutoff function operating productively EBV-infected B cells. This impairment protein synthesis results from mRNA degradation induced upon expression early lytic-cycle gene product BGLF5. Recently, 2 -herpesvirus, Kaposi sarcoma herpesvirus, has also been shown encode function,...
ABSTRACT The transforming Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) activates signalling on the NF-κB axis through two distinct domains in its cytoplasmic C terminus, namely, CTAR1 (amino acids [aa] 187 to 231) and CTAR2 (aa 351 386). ability of activate appears be attributable direct interaction tumor necrosis factor (TNF) receptor-associated 2 (TRAF2), while recent work indicates that CTAR2-induced is mediated association with TNF death domain (TRADD). LMP1 expression...
Infection of Epstein-Barr virus-negative human B-lymphoma cell lines with the fully transforming B95.8 virus strain was associated complete latent gene expression and a change in surface growth phenotype toward that vitro-transformed lymphoblastoid lines. In contrast, cells infected P3HR1 strain, deletion mutant cannot encode nuclear antigen 2 (EBNA2) or full-length EBNA-LP, expressed EBNAs1, 3a, 3b, 3c but were negative for membrane protein (LMP) showed no cellular phenotype. This suggests...
An ability of the Epstein-Barr virus latent membrane protein LMP1 to enhance survival infected B cells through upregulation bcl-2 oncogene was first suggested by experiments involving gene transfection and selection stable LMP1+ clones (S. Henderson, M. Rowe, C. Gregory, F. Wang, E. Kieff, A. Rickinson, Cell 65:1107-1115, 1991). However, it not possible ascertain whether Bcl-2 a specific consequence expression or an artifact procedure whereby rare Bcl-2+ already present in starting...
Abstract Group I Burkitt lymphoma (BL) lines retaining the original BL tumor cell phenotype are unable to present endogenously expressed antigens HLA class I‐restricted cytotoxic T cells (CTL) but can be recognized if relevant I/peptide epitope complex is reconstituted at surface by exogenous addition of synthetic target peptide. Endogenous antigen‐processing function restored in that have undergone Epstein‐Barr virus (EBV)‐induced drift culture group III typically displayed EBV‐transformed...